Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Stephens Annual Investment Conference at 11:00 a.m. ET (10:00 a.m. CT) on Thursday, November 20, 2025.

GlobeNewsWire • Nov 14, 2025

Wall Street Analysts Believe Vericel (VCEL) Could Rally 39.42%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Nov 10, 2025

Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings

Baltimore-based Brown Capital Management sold 861,020 shares of Vericel Corporation in the third quarter for an estimated $31 million. The transaction value represented 1.3% of Brown Capital's 13F reportable AUM as of quarter-end.

The Motley Fool • Nov 6, 2025

Vericel Corporation (VCEL) Q3 2025 Earnings Call Transcript

Vericel Corporation ( VCEL ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Eric Burns - Vice President of Finance & Investor Relations Dominick C. Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Richard Newitter - Truist Securities, Inc., Research Division Ryan Zimmerman - BTIG, LLC, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Michael Kratky - Leerink Partners LLC, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and welcome to the Vericel Corporation Third Quarter 2025 Earnings Call.

Seeking Alpha • Nov 6, 2025

Vericel Reports Third Quarter 2025 Financial Results

Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2025.

GlobeNewsWire • Nov 6, 2025

Vericel Corporation (VCEL) Q3 Earnings and Revenues Top Estimates

Vericel Corporation (VCEL) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.02 per share a year ago.

Zacks Investment Research • Nov 6, 2025

Is the Options Market Predicting a Spike in Vericel Stock?

Investors need to pay close attention to VCEL stock based on the movements in the options market lately.

Zacks Investment Research • Sep 11, 2025

Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Wells Fargo Healthcare Conference at 3:45 p.m. ET on Thursday, September 4, 2025.

GlobeNewsWire • Aug 28, 2025

Vericel Q2 Revenue Jumps 20%

Vericel Q2 Revenue Jumps 20%

The Motley Fool • Aug 5, 2025

Vericel Corporation (VCEL) Q2 2025 Earnings Call Transcript

Vericel Corporation (NASDAQ:VCEL ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Executives Dominick C. Colangelo – CEO, President & Director Eric Burns – Vice President of Finance & Investor Relations Joseph Anthony Mara – CFO & Treasurer Analysts Caitlin Cronin - Canaccord Genuity Corp., Research Division Mason Owen Carrico - Stephens Inc., Research Division Richard Samuel Newitter - Truist Securities, Inc., Research Division Ryan Benjamin Zimmerman - BTIG, LLC, Research Division Samuil-Hrabar Gatev - Leerink Partners LLC, Research Division Swayampakula Ramakanth - H.C.

Seeking Alpha • Jul 31, 2025